"Price increase first, then bargain" to cope with the collection?91 appraisal imitation pharmaceuticals are named

For the limited price of imitation pharmaceuticals, it is serious.

On July 29, the Hebei Provincial Medical Drug Instrument Concentrated Procurement Center issued an announcement to publicize drugs with problems with problems with excessive increases after passing consistency evaluation. Among them, there are 30 91 products with high evaluation products with high price increases, involving 50 companies including stone medicine group, Yichang Renfu, and North China Pharmaceutical.

The Jianzhi Bureau learned that according to the current policies, the evaluation products can "increase prices", and the price is generally not higher than the price of the original research product, but the specific increase does not clearly specify. This time, most of these products that were notified were more than 5 times that after the evaluation, which attracted the attention of the Hebei Provincial Recruitment Center.

Hebei Province requires that related issues need to explain the problems of the existence of the product. If the reason is not sufficient, the net cannot be hung.

At present, the national collection of drugs has been used, and many varieties of bargaining are more than 90%. Pharmaceutical companies have also "cried poor" and believed that the price was too low to affect subsequent research and development investment.

But this time, Hebei opened the window paper of the "price increase after review". Just like the e -commerce Double 11, the company may increase the price and then bargain, and the actual decline may not be great.

Evaluation varieties can increase prices, but not too high

Inquiry of the Jianzhi Bureau found that most of the high -priced price increases in Hebei Province have passed consistency evaluation since the second half of 2021.

Taking gastrointestinal drugs using Omeprazole sodium as an example, as many as 36 related products have been rated nationwide. Companies with high price increases include Zhejiang Kang Enbei, Lizhu Group, Stone Medicine Group and other 8 companies. Essence At present, this product is also one of the eighth batch of candidate varieties with the highest voices.

Another Mepatone tablet is a common termination of pregnancy drugs. It was originally the fifth batch of national collection of planning species, but it was not included in the end. The CPM new drug research and development monitoring database shows that the three products of Shanghai Xinhua Lianhe Pharmaceutical, Renfu Pharmaceutical, and China Resources Zizhu Pharmaceutical have passed consistency evaluation. Among them, the list of people's blessings and Zizhu in Hebei is "on the list".

Since the implementation of consistency evaluation rules, over -evaluation products can increase prices, which is considered to be in the industry.

Jianzhi Bureau learned from the enterprise that the current pharmaceutical pricing system of China is basically the original patent research> the first imitation> over -evaluation> ordinary GMP. Although the country's requirements for drug prices are "in principle, the general direction is price reduction", but in order to show fairness, as long as there are legitimate reasons, it can still be increased.

The businessman said: "Especially for products that have passed consistency evaluations, the company's evaluation has spent a lot of money, and the price adjustment is also reasonable. But how much is rising and how much is the rise? There is no unified statement. "

This part of the rules is blank, leaving a space for drilling. In June 2019, the Nantong City Health Commission of Jiangsu Province announced that due to the consistency evaluation, the price of Carer hydrochloride capsules with 0.15g of Pharmaceuticals rose from 0.3 yuan to 3.5 yuan One capsule, an increase of 1067%.

Similar situations have found in 2018 and 2019 nationwide collection. It has been mentioned less in the past two years. This is because localities have clearly stipulated the price increase after evaluation:

Taking Hebei Province as an example, in May this year, the Hebei Provincial Medical Drug Instrument Concentrated Procurement Center has announced that the price of the hanging network of drugs through consistency is not more expensive than the original product.

Nowadays, the Hebei Provincial Recruitment Center has a more specific scope of limited. Once the appraisal of the appraisal of the product is higher than the previous evaluation, or the highest price of the same quality level of the same variety, the highest price of the product is 5 times. Too high.

The above -mentioned varieties are too much price increases, so they were pulled out "appearance".

Consistency evaluation "new business"?

In 2015, the State Council issued the "Opinions on Reforming the Approval System for Reform of the Medical Devices for Medical Devices", which requires generic drug manufacturers to use the original variety as a reference preparation to carry out consistent evaluations of product treatment and efficacy.

The Jianzhi Bureau learned that consistency evaluation has put forward different previous requirements for the research and development of the enterprise and the strength of the capital: if the technical level and equipment of the enterprise are not complete, they can not be consistent evaluation at all; As a result, cost rises.

It is said that "the product of a consistency evaluation is equivalent to reorganizing a new drug."

Because of this, many of the "consistency evaluations" are traditional pharmaceutical companies with certain strength.

According to CPM new drug research and development monitoring database, the State Drug Administration has approved nearly 4800 consistency evaluation applications. Among them, there are more than a hundred approved articles from Qilu Pharmaceuticals and Stone Medicine Group, and the overlated varieties of large enterprises such as Bite Pharmaceutical, Coron Pharmaceutical, and Zhengda Tianqing have also reached more than 50.

In 2018, the national pharmaceutical collection policy was officially implemented. The selection variety was based on the consistency evaluation as the benchmark: when the number of original drugs and over -evaluating generic drugs of a certain product reached more than 3, it may be included in the collection list list Essence

The "over -evaluation" and the collection of collection have greatly increased the enthusiasm of enterprises to participate in consistency evaluation.

It is also during this period that more and more places began to subsidize consistency evaluations, and encouraged enterprises to seize the national market through collective collection.

The Jianzhi Bureau sorted out and found that most of the subsidies for a single variety for a single variety were concentrated from 1 million yuan to 5 million yuan, up to 15 million yuan.Some companies received a single subsidy of more than 20 million: In November 2018, Huahai Pharmaceutical announced that it received a consistent evaluation subsidy of 21 million yuan at one time.Earlier, Jianzhi Bureau learned from the enterprise that with the more and more rewards of various provinces, the purpose of some small enterprises to do consistency evaluation today is no longer to seize the market, but has become a simple subsidy.In some areas, the reward clause will even be directly indicated when attracting investment to attract companies to settle in the local area.

The company said: "The reward reward can basically cover the cost of enterprise investment. After passing consistency evaluation, these small pharmaceutical companies will send the products at low prices to collecting, which is enough to support themselves and can also have a good reputation."

These companies may not care about the results of collection, so they dare to increase their prices rapidly after the evaluation, and gain short -term excess benefits.

### ###

report

- END -